Cabtreo (Adapalene/Benzoyl/Clindamycin) Patent Expiration, LOE Window & CMS Spending

Cabtreo (Adapalene/Benzoyl/Clindamycin) by Bausch Health: FDA Orange Book LOE 2040-12-28, 0 AB generics, $4.5M 2024 CMS Part D & Medicaid spend, and $950 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBausch Health
FDA Application & PathwayN216632 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2040-12-28
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$4.5M
2024 Medicare Part D Spend$197K
2024 Medicaid Spend$4.3M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($950 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.